Author: Gambichler, T.; Scholl, L.; Dickel, H.; Ocker, L.; Stranzenbach, R.
Title: Prompt onset of Rowell's syndrome following the first BNT162b2 SARSâ€CoVâ€2 vaccination Cord-id: ehpo6lcp Document date: 2021_4_19
ID: ehpo6lcp
Snippet: In December 2020, the SARS-CoV-2 vaccine (BNT162b2, Comirnaty®, BioNTech/Pfizer) was approved by the European Medicines Agency. Recently, BNT162b2 was started to be administered to high-risk populations for COVID-19 in Germany.1 We here report the first case of an elderly patient who developed erythema multiforme after the first day of vaccination with BNT162b2.
Document: In December 2020, the SARS-CoV-2 vaccine (BNT162b2, Comirnaty®, BioNTech/Pfizer) was approved by the European Medicines Agency. Recently, BNT162b2 was started to be administered to high-risk populations for COVID-19 in Germany.1 We here report the first case of an elderly patient who developed erythema multiforme after the first day of vaccination with BNT162b2.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date